文献速递胸部肿瘤

IASLC关于晚期非小细胞肺癌液体活检的声明

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
PubMed 文献 · J Thorac Oncol · 2018-06-06

国际肺癌研究协会召集多学科专家小组,评估血浆循环肿瘤DNA检测在晚期非小细胞肺癌分子分析中的现有证据,旨在为临床管理提供推荐并识别未满足需求。小组认为液体活检有显著潜力改善患者照护,在多个治疗场景中立即临床应用是合理的。

要点

  • 血浆循环肿瘤DNA检测已进入临床实践,用于检测EGFR敏感和耐药突变。
  • ALK重排耐药突变等其它分子检测可能近期进入临床实践。
  • 液体活检在多个晚期NSCLC治疗场景中立即临床应用是合理的。

核心结论

  • 液体活检方法有显著潜力改善患者照护,在多个与NSCLC相关的治疗场景中立即临床应用是合理的。

研究设计与样本

  • 国际肺癌研究协会召集胸部肿瘤学、液体活检和分子病理学多学科专家小组评估现有证据并形成推荐。

主要发现

  • 血浆循环肿瘤DNA检测已进入临床实践,用于检测EGFR敏感和耐药突变。
  • 许多其它分子检测,如检测ALK重排耐药突变,可能近期进入临床实践。
  • 创新平台不仅提高分子分析保真度,还增加单一样本可进行的检测数量。

临床怎么用

  • 在多个晚期NSCLC治疗场景中,可立即将液体活检用于分子分析以指导临床管理。

局限性

  • 需评估液体活检的优缺点,并突出需要进一步研究的领域。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with considerable potential to improve clinical outcomes across multiple cancer types, including NSCLC. Assays of this nature that use blood as opposed to tumor samples are frequently referred to as liquid biopsies. An increasing number of innovative platforms have been recently developed that improve not only the fidelity of the molecular analysis but also the number of tests performed on a single specimen. Circulating tumor DNA assays for detection of both EGFR sensitizing and resistance mutations have already entered clinical practice and many other molecular tests - such as detection of resistance mutations for Anaplastic Lymphoma Kinase (ALK) receptor tyrosine kinase rearrangements - are likely to do so in the near future. Due to an abundance of new evidence, an appraisal was warranted to review strengths and weaknesses, to describe what is already in clinical practice and what has yet to be implemented, and to highlight areas in need of further investigation. A multidisciplinary panel of experts in the field of thoracic oncology with interest and expertise in liquid biopsy and molecular pathology was convened by the International Association for the Study of Lung Cancer to evaluate current available evidence with the aim of producing a set of recommendations for the use of liquid biopsy for molecular analysis in guiding the clinical management of advanced NSCLC patients as well as identifying unmet needs. In summary, the panel concluded that liquid biopsy approaches have significant potential to improve patient care, and immediate implementation in the clinic is justified in a number of therapeutic settings relevant to NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Rolfo C, Mack PC, Scagliotti GV, et al. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol. 2018. PMID: 29885479. doi:10.1016/j.jtho.2018.05.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。